Home > Listed Companies Info. > Main Board Companies

:::

:::Listed Companies > Listed Companies Info. > Main Board Companies > Listed Company Profile

General Stock Board Listed Company Profile

Code:

Industry:

Local/Foreign Company:

4157 TAIGEN

中文

Company Profile

Chairman

CEO

Spokesperson

Tel

Address

Date of Listing (Regular)

HUANG, KUO-LUNG

0281777020

Box 309, Ugland HouseGrand Cayman, KY1-1104, Cayman Islands

2014/01/17

Agent for litigious
and non-litigious matters

Tel of
Agent for litigious
and non-litigious matters

Address of
Agent for litigious
and non-litigious matters

HUANG, KUO-LUNG

0281777020

7F., NO. 138, XINMING RD., NEIHU DIST., TAIPEI CITY 11470, TAIWAN (R.O.C.)

Industry

Main Business

Biotechnology and Medical Care

Founded in 2001, TaiGen Biotechnology (TaiGen Taiwan) is a leading research- based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, China. In 2008, TaiGen Taiwan completed a share swap with TaiGen Biopharmaceuticals Holdings Limited (TaiGen Cayman), and has become a fully owned subsidiary of TaiGen Cayman. TaiGen's current pipeline includes therapeutics for infectious diseases, diabetic complications and cancer for the worldwide market. Nemonoxacin is a novel broad-spectrum non-fluorinated quinolone antibiotic under development for respiratory infections. In addition to nemonoxacin, TaiGen has two NCEs in clinical development under IND with US FDA: TG-0054, a chemokine receptor antagonist for stem cell transplantation and chemosensitization and TG-2349, a HCV protease inhibitor for treatment of chronic hepatitis infectio. Both TG- 0054 and TG-2349 are currently in clinical trials in patients in the US.

Shr. Vol.	Highest	Lowest	Closed	Change	Transaction	TurnOver(%)	long margin balance (1,000shr.)	Short margin balance (1,000shr.)
Market Information ( 2024/04/19 )
26229.623	17.25	16.20	16.45	0.70	9025	.00	10,994	16
Trading method	Fun purchase price or securities pneeded on T day	Announcement of Irregularity (2024/04/19)	TPEx measures adopted (2024/04/19)		With warrants	Can be shorted or margined?	Detail
Normal	N	N	N		Y	Y	Today	History

Financial Reports
Cash Flows	Items
	Items	Amount (NT$ thousand)
	Cash flows from operating activities
	Cash flows from investing activities
	Cash flows from financing activities
Balance Sheets	Current assets
	Non-current assets
	Total assets
	Current liabilities
	Non-current liabilities
	Total liabilities
	Share capital
	Capital surplus
	Retained earnings
	Other equity interest
	Treasury shares
	Total equity attributable to owners of parent
	Non-controlling interests
	Total equity
	Book Value per share(NT$)
Comprehensive Income	Operating revenue
	Operating costs
	Gross profit from operations
	Operating expenses
	Net other income (expenses)
	Net operating income
	Non-operating income and expenses
	Profit before tax
	Tax expense
	Profit from continuing operations
	Profit from discontinued operations
	Profit
	Other comprehensive income
	Comprehensive income
	Basic earnings per share

Auditor's report on latest financial statements： auditor's report：

More detail:MOPS。

Foreign issuers’ information is disclosed in consolidated statements.

TOP

TPEx

Listed Companies

General Stock Board Listed Company Profile